Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruiying Zhao

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Frontiers in Oncology|April 3, 2024
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutationsJiaqi Li, Mengqing Xie, Ruiying Zhao, et al.
Molecular Oncology|September 2, 2020
Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencingMeiying Cui, Yuchen Han, Pan Li, et al.
Chemistry Central Journal|November 24, 2012
Development and experimental test of support vector machines virtual screening method for searching Src inhibitors from large compound librariesBucong Han, Xiaohua Ma, Ruiying Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancerShuyuan Wang, Bo Zhang, Jie Qian, et al.
NPJ Precision Oncology|July 26, 2024
Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significanceShengnan Chen, Tao Hu, Jikai Zhao, et al.
Stem Cell Research|February 8, 2018
Generation of human embryonic stem cell line with heterozygous RB1 deletion by CRIPSR/Cas9 nickaseJian Tu, Zijun Huo, Mo Liu, et al.
Cell Cycle (Georgetown, Tex.)|February 21, 2013
CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicityRuiying Zhao, Heng-Yin Yang, Jihyun Shin, et al.
Cancer Research|March 17, 2006
DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancerHuiling Yang, Yu-Ye Wen, Ruiying Zhao, et al.
The Journal of Pathology. Clinical Research|March 26, 2021
Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese populationRuiying Zhao, Feng Yao, Chan Xiang, et al.
Frontiers in Immunology|September 5, 2022
An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysisLinping Gu, Xue Wang, Yile Sun, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Frontiers in Oncology|April 3, 2024
Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutationsJiaqi Li, Mengqing Xie, Ruiying Zhao, et al.
Molecular Oncology|September 2, 2020
Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencingMeiying Cui, Yuchen Han, Pan Li, et al.
Chemistry Central Journal|November 24, 2012
Development and experimental test of support vector machines virtual screening method for searching Src inhibitors from large compound librariesBucong Han, Xiaohua Ma, Ruiying Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancerShuyuan Wang, Bo Zhang, Jie Qian, et al.
NPJ Precision Oncology|July 26, 2024
Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significanceShengnan Chen, Tao Hu, Jikai Zhao, et al.
Stem Cell Research|February 8, 2018
Generation of human embryonic stem cell line with heterozygous RB1 deletion by CRIPSR/Cas9 nickaseJian Tu, Zijun Huo, Mo Liu, et al.
Cell Cycle (Georgetown, Tex.)|February 21, 2013
CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicityRuiying Zhao, Heng-Yin Yang, Jihyun Shin, et al.
Cancer Research|March 17, 2006
DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancerHuiling Yang, Yu-Ye Wen, Ruiying Zhao, et al.
The Journal of Pathology. Clinical Research|March 26, 2021
Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese populationRuiying Zhao, Feng Yao, Chan Xiang, et al.
Frontiers in Immunology|September 5, 2022
An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysisLinping Gu, Xue Wang, Yile Sun, et al.
Pageof 13